Report: Low Float, Vast Solid Pipeline and No Debt Make Ampio Attractive

(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 09/07/11 -- The drugs in Colorado based Ampio Pharmaceuticals' (NASDAQ: AMPE) portfolio target huge markets.

According to a new report, there are a fairly wide number of drugs being developed by the company and considering its size, that is an impressive feat. Speculators are anticipating new information regarding all 7 of its products undergoing clinical trials in the short term, including anticipated business outlook and licensing agreements for Zertane in the EU and Asia.

Ampio Pharmaceuticals is potentially in a strong position with their pipeline, targeting huge drug markets while maintaining minimal costs.

Given the current market conditions, does this relatively undiscovered biotech's valuation hold potential for explosive growth?

The full exclusive report by Brian Wilson, including details about the company's pipeline and upcoming news catalysts, is available now at:

In addition, investors interested in accessing BioMedReports' which can be used to make more profitable trades during today's volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com



Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 07.09.2011 - 11:01 Uhr
Sprache: Deutsch
News-ID 62795
Anzahl Zeichen: 0

contact information:
Town:

LOS ANGELES, CA

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 248 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Report: Low Float, Vast Solid Pipeline and No Debt Make Ampio Attractive"
steht unter der journalistisch-redaktionellen Verantwortung von

BioMedReports (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead ...

LOS ANGELES, CA -- (Marketwired) -- 11/06/13 -- In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed bioph ...

Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" ...

LOS ANGELES, CA -- (Marketwired) -- 08/01/13 -- With shares trading at heavily discounted price levels, speculative investors looking for a good bottom bounce trade should have their sights set on CEL-SCI Corporation (NYSE MKT: CVM) who last provide ...

Q&A With Coronado Biosciences CEO Harlan Weisman, M.D. ...

LOS ANGELES, CA -- (Marketwired) -- 07/23/13 -- It has been over a year since Coronado Biosciences, and the company, so we thought it time for an updated Q&A on this biopharmaceutical company that continues to be one of biotech's most talk ...

Alle Meldungen von BioMedReports